151 related articles for article (PubMed ID: 33380674)
21. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Dec; 18(4):e385-e393. PubMed ID: 31378656
[TBL] [Abstract][Full Text] [Related]
22. Inverse effect of mucinous component on survival in stage III colorectal cancer.
Ooki A; Akagi K; Yatsuoka T; Asayama M; Hara H; Yamamoto G; Nishimura Y; Yamaguchi K
J Surg Oncol; 2014 Dec; 110(7):851-7. PubMed ID: 25111953
[TBL] [Abstract][Full Text] [Related]
23. Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC.
Sluiter NR; Rovers KP; Salhi Y; Vlek SL; Coupé VMH; Verheul HMW; Kazemier G; de Hingh IHJT; Tuynman JB
Ann Surg Oncol; 2018 Aug; 25(8):2347-2356. PubMed ID: 29855834
[TBL] [Abstract][Full Text] [Related]
24. Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
Lan YT; Chang SC; Yang SH; Lin CC; Wang HS; Jiang JK; Chen WS; Lin TC; Chiou SH; Lin JK
Am J Surg; 2014 Jun; 207(6):922-30. PubMed ID: 24355407
[TBL] [Abstract][Full Text] [Related]
25. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
26. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
27. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case-control study.
Scarpa M; Ruffolo C; Erroi F; Fiorot A; Basato S; Pozza A; Canal F; Massani M; Cavallin F; Antoniutti M; Bassi N; Castoro C
Anticancer Res; 2014 Oct; 34(10):5735-41. PubMed ID: 25275082
[TBL] [Abstract][Full Text] [Related]
28. Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
Lee DW; Han SW; Cha Y; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Park JW; Ryoo SB; Jeong SY; Kang GH; Park KJ; Kim TY
BMC Cancer; 2015 Oct; 15():690. PubMed ID: 26467912
[TBL] [Abstract][Full Text] [Related]
29. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
30. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
31. Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients.
Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC
Ann Surg Oncol; 2013 Sep; 20(9):2914-20. PubMed ID: 23760586
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Outcome and Prognostic Factors of Sporadic Colorectal Cancer in Young Patients: A Large Institutional-Based Retrospective Study.
Kim TJ; Kim ER; Hong SN; Chang DK; Kim YH
Medicine (Baltimore); 2016 May; 95(19):e3641. PubMed ID: 27175682
[TBL] [Abstract][Full Text] [Related]
33. Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer.
Bergom C; Kelly T; Bedi M; Saeed H; Prior P; Rein LE; Szabo A; Wilson JF; Currey AD; White J
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):65-71. PubMed ID: 27511848
[TBL] [Abstract][Full Text] [Related]
34. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
[TBL] [Abstract][Full Text] [Related]
35. A paradox between preoperative overweight/obesity and change in weight during postoperative chemotherapy and its relationship to survival in stage Ⅱ and Ⅲ colorectal cancer patients.
Hu C; Zhang Q; Jin X; Zhang L; Zhang Y; Zhu Q; Tang M; Lyv G; Shi H
Clin Nutr; 2021 Apr; 40(4):2410-2419. PubMed ID: 33183882
[TBL] [Abstract][Full Text] [Related]
36. A high preoperative carbohydrate antigen 19-9 level is a risk factor for recurrence in stage II colorectal cancer.
Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Murono K; Watanabe T
Acta Oncol; 2017 May; 56(5):634-638. PubMed ID: 27885879
[TBL] [Abstract][Full Text] [Related]
37. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
[TBL] [Abstract][Full Text] [Related]
38. The Impact of Muscle and Adipose Tissue on Long-term Survival in Patients With Stage I to III Colorectal Cancer.
Hopkins JJ; Reif RL; Bigam DL; Baracos VE; Eurich DT; Sawyer MB
Dis Colon Rectum; 2019 May; 62(5):549-560. PubMed ID: 30789442
[TBL] [Abstract][Full Text] [Related]
39. Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy.
Fields AC; Lu P; Vierra BM; Hu F; Irani J; Bleday R; Goldberg JE; Nash GM; Melnitchouk N
Ann Surg Oncol; 2019 Apr; 26(4):1127-1133. PubMed ID: 30706232
[TBL] [Abstract][Full Text] [Related]
40. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma.
Lin M; Eng C; Hawk ET; Huang M; Lin J; Gu J; Ellis LM; Wu X
Cancer; 2012 Dec; 118(24):6188-98. PubMed ID: 22673945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
